VEGFA and Miyoshi myopathy: Our analysis results could also explain the lack of response to bevacizumab [43], a VEGFA inhibitor, since other types of vascular growth factors are highly expressed in the MM tumor microenvironment, leading to possible compensation and drug resistance.